Panoptix Trifocal Lens in Post Refractive Myopic Laser Vision Correction Surgery

Parkhurst NuVision Clinical Research

Status: Unknown

Conditions: Refractive Errors; Cataract

Treatments: Device: PanOptix Trifocal Intraocular Lens

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04698278

TFL210

Details and patient eligibility

About

The two main objectives of this study are to demonstrate safety and effectiveness of implanting the PanOptix Trifocal IOL in patients who have had previous myopic Lasik. The primary objectives to demonstrate clinical safety will be the quality of vision questionnaire (QUVID) which will demonstrate the patient's perception of halos, glares, and starbursts before and after the implantation of the trifocal IOL.

The primary objective to demonstrate clinical effectiveness will be done by measuring visual outcomes at distance, intermediate, and near. In addition, the patients will also fill out the spectacle independence questionnaire (IOLSAT Questionnaire) to determine their level of glasses independence postoperatively. In addition, at the conclusion of the study the patient will also fill out a patient satisfaction survey.

Full description

Clinical Hypothesis:

The rate of bothersome visual symptom items (defined as a very or extremely bothersome visual symptom that impacts daily living under overall condition) for the patients who are post-refractive who receive a PanOptix Trifocal IOL at the time of cataract surgery will be assessed. The bothersome visual symptom items of interest are halos, glare, and starbursts. Patients will also be assessed on level of glasses independence with an assessment of both corrected and uncorrected distance, intermediate, and near vision. Lastly patient satisfaction score will also be determined.

OVERALL STUDY DESIGN This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.

Duration:

6 months; however, any subject that undergoes a lens repositioning procedure due to IOL misalignment, or reports "very" or "extreme" overall bother that impacts daily living for any of the 3 defined bothersome visual symptoms (halos, glare, or starbursts) at 6 months, will be followed through 1 year postoperatively.

Administration:

Surgeons will perform routine small-incision, femtosecond laser assisted, cataract surgery and use the Alcon-recommended implantation systems for lens implantation. Refractive target outcomes will be emmetropia for both eyes.

Visit Schedule:

Subjects will be bilaterally implanted; the second eye is to be implanted within approximately one month after the first-eye surgery.

All subjects will undergo a minimum of 10 visits:

1. Preoperative for both eyes
2. Surgical Procedure for each individual eye
3. 1-day and 1-week visits for each eye
4. 1-month, 3-month, and 6-month visits for both eyes together
5. In addition, a 1-year postoperative visit will be required for subjects who undergo a lens repositioning procedure due to IOL misalignment at any time during the study, and for subjects who report "very" or "extreme" overall bother that impacts daily living for any of the 3 defined bothersome visual symptoms (halos, glare, or starbursts) at 6 months.

Enrollment: 20 estimated patients

Sex: All

Ages: 22+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Adults, 22 years of age or older at the time of surgery, diagnosed with bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision
2. Previous myopic Lasik with a well centered optical zone, corneal higher-order aberrations less than 0.6 um for a 4 mm pupil (measured by iTrace), and a minimum keratometric reading of 35.0 D.
3. Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures
4. Best Corrected Distance Visual Acuity (BCDVA) projected to be 0.2 logMAR (Minimum Angle of Resolution) or better
5. Calculated lens power within the available range
6. Preoperative keratometric astigmatism at or less than 2.5 D in both operative eyes
7. Clear intraocular media other than cataract in both eyes

Exclusion criteria

1. Clinically significant corneal abnormalities including corneal dystrophy, irregularity, inflammation or edema.
2. Previous intraocular surgery other than myopic Lasik
3. History of or current retinal conditions or predisposition to retinal conditions
4. Amblyopia
5. Rubella, congenital, traumatic, or complicated cataracts
6. History of or current anterior or posterior segment inflammation of any etiology
7. Iris neovascularization
8. Glaucoma (uncontrolled or controlled with medication)
9. Optic nerve atrophy
10. Subjects with diagnosed degenerative eye disorders
11. Pregnancy or lactation
12. Any disease or pathology, other than cataract, that is expected to reduce the potential postoperative BCDVA to a level worse than 0.30 logMAR.

Trial design

20 participants in 1 patient group

Surgical Treatment Group

Description:

This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.

Treatment:

Device: PanOptix Trifocal Intraocular Lens